CXCL9 and cancer: Of these mechanisms we believe that the most important one is the immune-related mechanism because of its potential relevance for cancer immunotherapies, either as CXCL9 or CXCL10 based monotherapies or in combination with well-established immune checkpoint inhibitors (ICI) including anti-CTLA-4 mAb, anti-PD-1 mAb, and anti-PD-L1 mAb [21,22,23,25,26,28,29,33,37,195] to possibly increase the efficacy of response to ICI.